Secondary Commercial Exploitation of Donated Tissue: Legality

Introduction

Secondary commercial exploitation of donated tissue refers to the use of human tissue, cells, blood, organs, or biological samples for a commercial purpose different from the original purpose for which they were donated. Examples include using tissue collected for diagnosis in pharmaceutical research, developing a commercial genetic test, producing cell-based therapies, or using biological samples to create a patented research product.

The legal issue is whether the original donation and consent permit later commercial use, whether the donor’s privacy and dignity are protected, and whether a company or researcher may obtain commercial benefits from the donated material.

In India, the legality depends on the type of tissue, the purpose of use, the consent obtained, and the applicable regulatory framework. Donation does not automatically mean unrestricted commercial use. A distinction must be made between prohibited commercial trading in human organs and the regulated use of donated tissue or biospecimens for research and product development.

Legal Framework in India

The Transplantation of Human Organs and Tissues Act, 1994 (THOTA) regulates removal, storage, and transplantation of human organs and tissues for therapeutic purposes and prohibits commercial dealings. Section 19A specifically penalizes certain payment-based dealings in human tissues, including receiving or making payment for supply of tissue.

India Code+1

However, not every commercial use of donated tissue is necessarily the same as illegal tissue trading. A key distinction is between:

Payment for the tissue itself, which may be prohibited under THOTA;

Legitimate research or product development using donated tissue under appropriate consent, ethics review, and applicable regulation;

Commercial sale of a processed tissue-derived product, which requires separate legal analysis and cannot be assumed lawful merely because the material has been processed.

The ICMR National Ethical Guidelines address biobanking, secondary use, material transfer, consent, commercial value, and benefit-sharing. They call for consent that appropriately covers future research and potential commercial use, and for institutional ethics review of biospecimen transfers and research proposals.

PMC

Case Laws

1. Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990)

The California Supreme Court considered a patient’s claim after doctors used his cells to develop a commercially valuable cell line without disclosing their financial interests. The majority rejected the patient’s conversion claim over the excised cells but allowed claims based on failure to disclose material information and breach of informed consent to proceed. The case is important because it distinguishes ownership of removed tissue from a donor’s right to informed disclosure of research and commercial interests. It is a foreign judgment and not binding in India.

Indian Journal of Medical Ethics

2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

The Supreme Court of India held that consent for one medical procedure does not automatically authorize a different or additional procedure. Consent must be informed and relate to the intervention proposed. Applied by analogy to tissue donation, consent for diagnosis or treatment should not automatically be treated as permission for unrelated secondary commercial research, particularly where the commercial purpose was not disclosed. The case did not directly decide commercial exploitation of donated tissue.

Indian Journal of Medical Ethics

3. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

The Supreme Court recognized privacy as a fundamental right under Article 21, including informational privacy and personal autonomy. This principle is relevant where donated tissue is linked to genetic or health data. Secondary use that permits identification or exposes sensitive information may raise privacy concerns, even if the tissue was originally donated.

Indian Journal of Medical Ethics

Legality and Conclusion

The legality of secondary commercial exploitation depends on the donor’s consent, the nature of the tissue, whether payment is made for the tissue itself, applicable ethics review, and safeguards for privacy and biosafety.

A lawful research or commercial pathway should ordinarily include:

Clear consent covering secondary research and possible commercial applications;

Ethics committee review where required;

Appropriate de-identification and confidentiality safeguards;

A material transfer agreement for sharing biospecimens;

Compliance with THOTA where human tissues are covered by its commercial-dealing prohibition;

Transparent terms concerning commercial interests and any proposed benefit-sharing.

In conclusion, donated tissue is not automatically free for unrestricted commercial exploitation. Indian law prohibits certain commercial dealings in human tissues, while ethical guidelines regulate research and secondary use. The cited cases support informed consent, autonomy, and privacy, but they are not direct Supreme Court rulings on commercial exploitation of donated research tissue. The central legal requirement is to respect donor authorization and prevent prohibited tissue trading, while allowing properly regulated scientific research and product development.